Grant Funding Opportunities: 4/21/2014
Weekly Grant Funding Opportunities
Please feel free to send special funding search requests any time (susan_craft@ncbiotech.org). Grant funding requests are included our regular research and include a fee of $100/hour. Also, let us know if any of your partners have submitted grant applications to funding announcements posted in the weekly grant alert emails. We would love to hear of their successes!
Visit NCBiotech’s Funding Gateway page to get more information on funding announcements, links to opportunity search databases and grant development tips.
Announcements
NCET2 is offering two courses: Applying to the NSF SBIR Phase I Program for First-Time Applicants (April 29 and 30) and Applying to the NIH SBIR Phase I Program for First-Time Applicants (June 2 and 3). Each course is a step-by-step, four hour online “How-To” workshops over two evenings, offered at an introductory price of $995.
Upcoming Deadlines
Deadline: 5/1/2014
Agency: Food and Drug Administration
Program: Dissolution Methods for Microsphere and Implant Drug Products
Description: Dissolution testing is recommended as part of the demonstration of bioequivalence between test and reference products in the approval of most generic drugs. Drug release measurements are useful for evaluating the effect of manufacturing differences and to assess performance characteristics of a sustained release dosage form. Generally, a generic drug product intended for parenteral use contains the same inactive ingredients (“Q1”) and in the same concentration (“Q2”) as the Reference Listed Drug (RLD). However, there may be differences in manufacturing of the generic and RLD products, which may affect bioavailability. Dissolution testing can be used as one of several standard methods to evaluate physicochemical differences of the drug product caused by manufacturing differences. The purpose of this study is to investigate dissolution methods for a parenteral sustained release drug product. The results from this study will help the FDA in developing recommendations to determine bioequivalence of generic parenteral sustained release drug products.
Award Amount: $400,000 - 500,000
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-14-007.html
Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others
Deadline: 5/6/2014
Agency: Bill and Melinda Gates Foundation
Program: Grand Challenges Explorations Round 13
Description: Grand Challenges Explorations fosters innovation in global health research. The Bill & Melinda Gates Foundation has committed $100 million to encourage scientists worldwide to expand the pipeline of ideas to fight our greatest health challenges. For each round of Grand Challenges Explorations, applicants are asked to focus their proposals on specific topics where creative, unorthodox thinking is most urgently needed. Explorations Round 13 topics include:
New Ways of Working Together: Integrating Community-Based Interventions - new!
Explore New Ways to Measure Fetal and Infant Brain Development - new!
Inciting Healthy Behaviors: nudge, disrupt, leapfrog, reach
Novel Enabling Tools and Models Supporting Development of Interventions for Enteric Dysfunction
Innovations in Feedback & Accountability Systems for Agricultural Development
Award Amount: $100,000
Website: www.grandchallenges.org/explorations/Pages/introduction.aspx
Eligibility: The grant program is open to anyone from any discipline, from student to tenured professor, and from any organization – colleges and universities, government laboratories, research institutions, non-profit organizations and for-profit companies.
New Opportunities
Deadline: 5/23/2014
Agency: Department of Energy
Program: Bioenergy Technologies Incubator
Description: The Office of Energy Efficiency and Renewable Energy (EERE) will issue, on behalf of the Bioenergy Technologies Office (BETO), a Funding Opportunity Announcement (FOA) entitled Bioenergy Technologies Incubator. BETOs mission is to engage in research and development (R&D) and demonstration at increasing scale activities to transform renewable biomass resources into commercially viable, high-performance biofuels, and bioproducts and biopower that enable biofuel production. To accomplish this mission, BETO develops a strategic plan, or multi-year program plan, to identify the technical challenges and barriers that need to be overcome. However, BETO recognizes that there may be novel and potentially disruptive ideas that do not necessarily align well with BETOs current multi-year program plan yet still meet the goals and mission of BETO. The Bioenergy Incubator Program is intended to identify these potentially impactful technologies and solutions that are not meaningfully addressed in BETOs strategic plan or project portfolio. It is NOT intended to fund projects that are incremental improvements to current products or processes or for established work in BETOs strategic plan or current portfolio. The Bioenergy Technologies Incubator FOA will be open to any and all impactful proposals which significantly advance the mission of the BETO. It is expected that proposals will be at early Technology Readiness Levels (TRL) ranging from 2 (Technology concept and/or application formulated) to 4 (Component and/or breadboard validation in laboratory environment). Successful incubator projects will reduce the risk associated with potentially breakthrough approaches and technologies so that they could be viable candidates in future program roadmaps.
Award Amount: Varies
Website: https://eere-exchange.energy.gov/#FoaId28e0ebed-de32-4b3a-97f3-4184df7f5420
Eligibility: Unrestricted
Deadline: 6/1/2014
Agency: Food and Drug Administration
Program: Physiologically Based Absorption and Pharmacokinetic Modeling and Simulation for Non-gastrointestinally Absorbed Drug Products In Humans
Description: Evaluation of equivalence for complex drug products, such as locally acting drug products and non-biological complex parenteral drug products, is challenging. In general, the challenges for those drug products are to relate critical quality contributes to in vitro performance, to relate in vitro performance to in vivo performance, including drug distribution at the site of action and plasma drug distribution, and ultimately to relate in vitro drug performance to clinical performance. Physiologically based absorption and PK models capture the best current understanding of the complex interplay between product attributes and human physiology. Therefore they can aid FDA in developing regulatory science and policies in these complex areas and aid the generic industry in designing high quality products that meet public expectations for equivalence. Objectives: The objectives of this project are to develop, evaluate and improve physiologically based absorption and pharmacokinetic models for the following areas to support and facilitate generic drug guidance development, product development, and application review, in these areas. Subtopic 1: Physiologically based pharmacokinetic modelling and simulation of dermal absorption. Subtopic 2: Physiologically based pharmacokinetic modelling and simulation of ocular absorption. Subtopic 3: Physiologically based pharmacokinetic modelling and simulation for non-biological complex parenteral drug products (including liposomes, nanosuspension, micelles, microspheres, implants, and hydrogels). Subtopic 4: Physiologically based pharmacokinetic modelling and simulation of lung absorption via oral inhalation. Subtopic 5: Physiologically based pharmacokinetic modelling and simulation of absorption from nasally delivered products (including nasal solutions, suspensions as well as nasal insufflation as a potential route of abuse).
Award Amount: $150,000 - 200,000
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-14-012.html
Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others
Deadline: 6/3/2014
Agency: Food and Drug Administration
Program: Evaluation of in vitro release methods for liposomal drug products
Description: The development of generic liposomal drug products is challenged by a lack of compendial or bio-relevant in vitro release methods. The traditional in vitro release method relies on dialyzing the liposomal formulation against a large volume of buffer. This method suffers from poor in vivo predictive power due to its inability to mimic the complex in vivo release conditions such as the large membrane pool present in systemic circulation or drug release conditions at the tumor sites or in the macrophages. Modifications to the traditional method include dialyzing against serum, serum protein solution, or surfactant solution and performing multiple stage dialyses. In addition, advances in separation techniques, such as filtration, centrifugation, and solid phase extraction, makes possible novel in vitro release assays in the presence of excess acceptor multilamellar or unilamellar vesicles. The robustness and predictive power of these methods have not been systemically evaluated or compared for specific type of liposomal drug products. The optimization and establishment of a standard in vitro release assay will advance the regulatory review of generic liposomal product applications. Objectives: The purpose of this study is to evaluate different in vitro release methods for liposomal drug products and analyze their robustness, capability of detecting formulation differences, and predictive power for in vivo performance. This study is intended to advance the regulatory review process of generic liposomal drug products, which in turn will help provide the US public with access to high quality generic liposomal drug products.
Award Amount: $450,000 - 500,000
Website: www.grants.gov/web/grants/view-opportunity.html?oppId=253192
Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others
Deadline: 6/15/2014 (LOI); 7/15/2014 (application)
Agency: National Institutes of Health
Program: Targeting Latently Infected Cells Without Reactivation (R01)
Description: The purpose of this Funding Opportunity Announcement (FOA) is to solicit innovative research that advances the understanding of mechanisms or approaches that could be harnessed to selectively eliminate HIV-1 latently-infected cells without depending on viral reactivation. The ultimate goal is to inform the design of future therapeutic approaches that could be used to eradicate the latent reservoir that persists in the context of optimally suppressive highly active antiretroviral therapy (HAART), thereby affecting a permanent cure for HIV infection. Cross-disciplinary collaborations enabling technology-driven strategies are strongly encouraged.
Award Amount: Varies
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-021.html
Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others